Request Information Permalink

LIPOXIN MEDIATED NEUROPROTECTION

Tech ID: 27404 / UC Case 2017-109-0

PATENT STATUS

Country	Туре	Number	Dated	Case
United States Of America	Issued Patent	11,439,615	09/13/2022	2017-109
Canada	Published Application			2017-109

BRIEF DESCRIPTION

This is small molecule neuroprotective activity secreted from resting astrocytes in the inner retina, where neighboring retinal ganglion cell neurons (RGCs) are vulnerable to irreversible damage in the neurodegenerative disease glaucoma.

SUGGESTED USES

Therapeutic treatment with LXB $_4$ is efficacious in both pathological and functional measures in a chronic glaucoma model. Together, these results indicate a novel resident neuroprotective mechanism for LXB $_4$ that can become deficient following neuronal injury. Restoration of this balance suggests a therapeutic potential.

ADVANTAGES

The role and regulation of labile small molecule factors in neuroinflammation and neurodegeneration is not well understood. This small molecule has neuroprotective activity secreted from resting astrocytes in the inner retina, where neighboring retinal ganglion cell neurons (RGCs) are vulnerable to irreversible damage in the neurodegenerative disease glaucoma.

RELATED MATERIALS

CONTACT

Craig K. Kennedy craig.kennedy@berkeley.edu tel: .



INVENTORS

>> Flanagan, John G.

OTHER INFORMATION

KEYWORDS

Retinal, Glaucoma

CATEGORIZED AS

» Medical

» Disease: Ophthalmology and Optometry

RELATED CASES

2017-109-0



University of California, Berkeley Office of Technology Licensing

2150 Shattuck Avenue, Suite 510, Berkeley,CA 94704

Tel: 510.643.7201 | Fax: 510.642.4566

https://ipira.berkeley.edu/ | otl-feedback@lists.berkeley.edu

© 2022, The Regents of the University of California

Terms of use | Privacy Notice